Call Us: 1.800.873.5297

By

Recent Yaz/Yasmin News

November 2, 2011

New Study Confirms the Dangers of Yaz, Yasmin, and Ocella

A study published in the British Medical Journal on October 25, 2011 confirms that Yaz, Yasmin and Ocella are at least twice more likely to cause dangerous blood clots than other types of birth control pills.

All birth control pills carry some risk of causing blood clots. However, recent studies have shown that Yaz, Yasmin, and Ocella may carry a higher risk of causing blood clots than other birth control pills. Birth control pills contain two types of hormones, estrogen and progestin. It is drospirenone, the progestin in Yaz, Yasmin, and Ocella, that researchers believe is to blame for the increased incidence of blood clots that occurs with those pills. The new study found that women who use birth control pills containing drospirenone are at least twice as likely to suffer from blood clots as women that use birth control pills that contain levonorgestrel, a different type of progestin. The study is available here

This study confirms previous concerns about these pills. In April 2011, the British Medical Journal published two studies that also found that Yaz, Yasmin, and Ocellla users suffer more blood clots that women who use other types of birth control pills. The new study was a large-scale study designed to confirm these previous findings.

The authors of these studies have concluded that Yaz, Yasmin, and Ocella are “not as safe” as other birth control pills, and “should not be the first choice in oral contraception.” Furthermore, the authors found that “no clear evidence exists to show that the drospirenone pill confers benefits above those of other oral contraceptives in preventing pregnancy, treating acne, alleviating premenstrual syndrome, or avoiding weight gain.” In other words, the researchers found that Yaz, Yasmin, and Ocella do not provide any benefits that other, safer, birth control pills do not have, and there is no medical reason to use Yaz, Yasmin, or Ocella instead of a safer birth control pill.

October 15, 2011

ABC News Investigation: New Studies Find Yaz More Risky Than Other Leading Birth Control Pills.

ABC News covers the story of Carissa Ubersox, a young pediatric nurse who blames Yaz for nearly killing her, and causing her to go blind at the age of 24. As reported by ABC, while all birth control pills carry some risk, multiple studies show that Yaz has a two to three times higher risk than other birth control pills. That is, Yaz users are two to three times more likely to suffer blood clots than users of other birth control pills, according to the studies. Blood clots can cause death and serious, permanent injuries.

For more information, see the links below.

May 15, 2011

 

FDA Warns of Increased Risk of Blood Clots associated with Yaz, Yasmin, and Ocella

The FDA is further reviewing the risk and expects to have results of its investigation later this summer.

On May 31, 2011, the Food and Drug Administration (FDA) issued a Safety Alert directed to women who use Yaz, Yasmin, Ocella, and other drospirenone-containing birth control pills. The warning announces that two recently published studies report a greater risk of suffering a blood clot associated with birth control pills that contain drospirenone than with other birth control pills. The two studies showed that women who use Yaz, Yasmin or Ocella have a 2-3 times greater risk of suffering a blood clot than women who use birth control pills that contain levonorgestrel (and not drospirenone), such as Alesse, Nordette, Triphasil, or Trivora. The studies are available for free on the British Medical Journal’s website, at the following links:

Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database, by Lianne Parkin, Katrina Sharples, Rohini Hernandez, and Susan Jick: http://www.bmj.com/content/342/bmj.d2139.full

Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data, by Susan Jick and Rohini Hernandez: http://www.bmj.com/content/342/bmj.d2151.full

Most birth control pills contain two types of hormones, an estrogen and a progestin. Drospirenone is the progestin hormone contained in the birth control pills Yaz, Yasmin, and Ocella. Other birth control pills use different progestin hormones, for example levonorgestrel or norgestimate.  A list of birth control pills that contain drospirenone is available here:http://www.fda.gov/Drugs/DrugSafety/ucm257164.htm#table1.

The FDA recommends that women using Yaz, Yasmin, or Ocella consult their healthcare provider before they stop using the pills. The FDA also recommends that women using Yaz, Yasmin or Ocella contact their healthcare provider immediately if they develop symptoms of a blood clot, such as persistent leg pain, severe chest pain, or sudden shortness of breath.

Blood clots are also known as venous thromboembolisms (VTE). A blood clot that forms in a vein deep in the body might also be called a deep vein thrombosis (DVT). A blood clot that forms in or travels to the lung is also called a pulmonary embolism (PE).

The FDA encourages anyone who has suffered an adverse event or side effect while using Yaz, Yasmin, or Ocella to report it to the FDA through their MedWatch Safety Information and Adverse Event Reporting Program. An Adverse Event report can be submitted to the FDA either online at www.fda.gov/MedWatch/report.htm, or by calling 1-800-332-1088.

The FDA’s warning is available here:http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm257337.htm.

Additional information from the FDA regarding the safety of Yaz, Yasmin and Ocella is available here: http://www.fda.gov/Drugs/DrugSafety/ucm257164.htm.

The FDA has also provided a list of questions and answers about birth control pills containing drospirenone and the risk of blood clots, available here:http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm257175.htm.

If you or someone you love has been injured by Yaz, Yasmin, or Ocella, contact the attorneys at Schlichter, Bogard, and Denton for a free consultation.

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.